Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in ...

Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Checkpoint inhibitors such as tislelizumab have improved ... the Company is taking a major step towards realizing the full potential of its Decoy platform. About Indaptus Therapeutics Indaptus ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Sun Pharmaceutical Industries Ltd’s latest acquisition of US-based Checkpoint Therapeutics, Inc. is good news for its speciality business–an area of focus. Checkpoint is an immunotherapy and ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Ratings ...